Suramin, an active drug for prostate cancer: Interim observations in a phase I trial

Journal of the National Cancer Institute

Volumn 85, Issue 8, 1993, Pages 611-621

  Eisenberger, Mario A ^a   Reyno, Leonard M ^a   Jodrell, Duncan I ^a   Sinibaldi, Victoria J ^a   Tkaczuk, Katherine H ^a   Sridhara, Rajeshwari ^a   Zuhowski, Eleanor G ^a   Lowitt, Mark H ^b   Jacobs, Stephen C ^b   Egorin, Merrill J ^a  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; CALCIUM ION; CREATINE KINASE; CREATININE; FLUTAMIDE; GLUCOSE; GONADORELIN DERIVATIVE; HYDROCORTISONE; LEUPRORELIN; MAGNESIUM ION; POTASSIUM ION; PROSTATE SPECIFIC ANTIGEN; SODIUM ION; SURAMIN; TESTOSTERONE; TRIACYLGLYCEROL LIPASE; VITAMIN K GROUP;

ADRENAL INSUFFICIENCY; ADULT; AGED; ANEMIA; ARTICLE; BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; FATIGUE; FEVER; HUMAN; HYPERGLYCEMIA; INFECTION; INTRAMUSCULAR DRUG ADMINISTRATION; KERATOPATHY; KIDNEY FAILURE; LETHARGY; LYMPHOCYTOPENIA; MALAISE; MALE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RASH; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMAN; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGE; PROSTATIC NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; SURAMIN; TREATMENT OUTCOME;

EID: 0027471478     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/85.8.611     Document Type: Article

References (41)

1. Tanon I, Janot E: Essai de iraitement de la maladie du sommeil, au Cameroun, par le Bayer 205. Action sur les parasites. Action sur le rein de foie. Ann Parasit Hum Comp 2:327-334, 1924
2. Broder S, Yarchoan R, Collins JM, et al: Effects of suramin on HTLV-lll/LAV infection presenting as Kaposi’s sarcoma or A1DS-related complex: Clinical pharmacology and suppression of virus replication in vivo. Lancet 2:627-630, 1985
3. De Clerq E: Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett 8:9-22, 1979
4. Mitsuya H, Popovic M, Yarchoan R, et al: Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science 276:172-174, 1984
5. Levine AM, Gill PS, Cohen J, et al: Suramin antiviral therapy in the acquired immunodeficiency syndrome. Clinical, immunological, and virologic results. Ann Intern Med 105:32-37, 1986
6. Stein CA, La Rocca R, Myers C: Suramin: An Old Compound With New Biology. PPO updates. In Principles & Practice of Oncology, vol. 4 (DeVita VT Jr, Heilman S, Rosenberg S, eds). Philadelphia: Lippincott, 1990
7. Fruehauf JP, Myers CE, Sinha BK: Synergistic activity of suramin with tumor necrosis factor alpha and doxorubicin on human prostate cancer lines. J Natl Cancer Inst 82:1206-1209, 1990
8. Kim JH, Sherwood ER, Sutkowski DM, et al: Inhibition of prostatic tumor cell proliferation by suramin: Alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution. J Urol 146:171176, 1991
9. Vignon F, Prebois C, Rochefort H: Inhibition of breast cancer growth by suramin. J Natl Cancer Inst 84:38-42, 1992
10. Taylor CW, Lui R, Fanta P, et al: Effects of suramin on in vitro growth of fresh human tumors. J Natl Cancer Inst 84:489-494, 1992
11. Fantini J, Rognoni JB, Roccabianca M, et al: Suramin inhibits cell growth and glycolytic activity and triggers differentiation in human colonic adenocarcinoma cell clone HT-29-D4. J Biol Chem 264:10282-10286, 1989
12. Hargis JB, Danesi R, Myers C, et al: Suramin activity in human sarcoma cell lines. Proc Am Assoc Cancer Res 31.410, 1990
13. Spigelman Z, Dowers A, Kennedy S, et al' Antiproliferative effects of suramin on lymphoid cells. Cancer Res 47:4696-4698, 1987
14. Freter C, Wolfson A, Brown A, et al: Dexamethasone and suramin block lymphoid tumor cells in different phases of the cell cycle. Proc Am Assoc Cancer Res 31:345, 1990
15. Daniel R, La Rocca R, Stein C, et al: Effect of suramin on the human glioma cell line U796T. Proc Am Assoc Cancer Res 30:578, 1989
16. Myers C, La Rocca RV, Cooper MR, et al: Role of suramin in cancer biology and treatment. In Molecular Foundations of Oncology (Broder S, ed). Baltimore: Williams & Wilkins, 1991, pp 413-431
17. Hosang M: Suramin binds to platelet-derived growth factor and inhibits biological activity. J Cell Biochem 29.265-273, 1985
18. Moscatelli D, Quarto N: Transformation of NIH 3T3 cells with basic fibroblast growth factor or the hst/k-fgf oncogene causes down regulation of the fibroblast growth factor receptor: Reversal of morphological transformation and restoration of receptor number by suramin. J Cell Biol 109:2519-2527, 1989
19. Wilding G, Zugmeier G, Knabbe C, et al: The role of transforming growth factors A and B in human prostate cancer cell growth. Proc Am Assoc Cancer Res 29:241, 1988
20. Elson SD, Browne CA, Thorburn GD: Identification of epidermal growth factor-like activity in human male reproductive tissue and fluids. J Clin Endocrinol Metab 58:589-594, 1984
21. Pollak M, Richard M: Suramin blockade of insulin-like growth factor I-stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst 82:1349-1352, 1990
22. Stein CA, La Rocca RV, Thomas R, et al: Suramin: An anticancer drug with a unique mechanism of action. J Clin Oncol 7:499-508, 1989
23. Myers C, Cooper M, Stein C, et al: Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881-889, 1992
24. Collins JM, Klecker RW Jr., Yarchoan R, et au Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol 26:22-26, 1986
25. Scher HI, Jodrell D, Inversen JM, et al: Use of adaptive control with feedback to individualize suramin dosing. Cancer Res 52:64-70, 1992
26. Jodrell D, Zuhowski E, Egorin M, et al: Intermittent bolus dosing with suramin: The use of adaptive control with feedback. Proc ASCO 10:237, 1991
27. Eisenberger M, Jodrell D, Sinibaldi V, et al: Preliminary evidence of antitumor activity against prostate cancer observed in a phase I trial with suramin. Proc ASCO 10:537, 1991
28. Tong WP, Scher NI, Petrycak DP, et al: A rapid assay of suramin in plasma. J Liq Chrom 13:2269-2284, 1990
29. Sheiner LB, Beal S, Rosenberg B, et al: Forecasting individual pharmacokinetics. Clin Pharmacol Ther 26:294-305, 1979
30. Jodrell DI, Zuhowski E, Egorin MJ, et al: Adaptive control with feedback (ACF) allows safe administration of suramin by intermittent infusion. Eur J Cancer 27:195, 1991
31. La Rocca RV, Meer J, Gilliat RW, et al: Suramin induced polyneuropathy. Neurology 40:954-960, 1990
32. Greoory LC, Eisenberger M, Sinibaldi V, et al: Suramin interferes with measurements of total calcium and serum amylase by the Kodak Ektachem 700 analyzer and may inhibit liver enzyme activity. Clin Chem 38:2552-2553, 1992
33. Stein CA, Saville W, Yarchoan R, et al: Suramin and function of the adrenal cortex. Ann Intern Med 104:286-287, 1986
34. Ashby H, DiMattina M, Llnehan WM, et al: The inhibition of human adrenal steroidogenic enzyme activities by suramin J Clin Endocrinol Metab 68:505-508, 1989
35. Eisenberger MA, Simon R, O'Dwyer PJ, et al: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostate carcinoma J Clin Oncol 3:827-841, 1985
36. Crawford ED: Hormonal therapy of prostatic carcinoma. Defining the challenge. Cancer 66:1035-1038, 1990
37. Stamey TA, Kabaljn LN, Ferrari M, et al: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. rV:Anti-androgen treated patients. J Urol 141:1088-1090, 1989
38. Cooper EH, Armitage TG, Robinson MRG, et al: Prostate specific antigen and the prediction of prognosis in metastatic prostate cancer. Cancer 66:1025-1028, 1990
39. Miller JI, Ahmann F, Drach GW, et al: The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147:956-961, 1992
40. Seidman AD, Scher HI, Petrylak DD, et al: Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 147:931-934, 1992
41. Scher HI, Cureey T, Geller N, et al: Trimetrexate in prostatic cancer Preliminary observations on the use of prostate-specific androgen and acid phosphatase as a marker in measurable hormone-refractory disease. J Clin Oncol 8:1830-1877, 1990.